Date |
Content |
12/27/2022 |
Weekly Broadcast |
12/19/2022 |
Weekly Broadcast |
12/12/2022 |
Weekly Broadcast |
12/8/2022 |
NRG-GY018 Patients Entered to Step 1 Can Proceed to Step 2 |
12/5/2022 |
Weekly Broadcast |
12/2/2022 |
NRG-BR005 Permanent Study Closure |
12/2/2022 |
NRG-BN010 Temporarily Closed to Accrual |
11/30/2022 |
NRG-GY018 Anticipated Closure to Accrual |
11/28/2022 |
Weekly Broadcast |
11/21/2022 |
Weekly Broadcast |
11/14/2022 |
Weekly Broadcast |
11/7/2022 |
Weekly Broadcast |
10/31/2022 |
Weekly Broadcast |
10/24/2022 |
Weekly Broadcast |
10/17/2022 |
Weekly Broadcast |
10/10/2022 |
Weekly Broadcast: NRG-GY005, NRG-GY022, NRG-GI008, GOG-0210, GOG-0238, GOG-0258, GOG-0263, NRG-GY006 |
10/3/2022 |
Weekly Broadcast: NRG-HN010, NRG-GY022, NSABP B-55/BIG 6-13, NRG-GU011, NRG-GY006, GOG 0210 |
9/26/2022 |
Weekly Broadcast: NRG-BN010, NRG-GU007, NRG-GY006, NRG-BR004, NRG-LU005, NRG-GY022, NRG-BN012, NRG-GI008, NRG-GU012, NRG-GY003, NRG-GY003, GOG-0210 |
9/26/2022 |
NRG-BN010 Reopen to Safety Run-In/Dose Level 2 |
9/26/2022 |
NRG-GU007 Reopen to Dose Level 3 |
9/19/2022 |
Weekly Broadcast: NRG-CC010, NRG-GY022, NRG-GY014, NRG-GI003, NRG-GY023, NRG-GY006, GOG-0210 |
9/12/2022 |
Weekly Broadcast: NRG-DT001, NRG-GY022, NRG-GU012, NRG-GY006, GOG-0210, NRG-LU002 |
9/6/2022 |
Weekly Broadcast: NRG-BN012, NRG-GU002, NRG-GY020, NRG-HN004, NRG-DT001, NRG-GY022, NRG-CC005/FORTE, NRG-GI005, NRG-GI008, NRG-GY006, GOG-0210 |
8/31/2022 |
NRG-BN012 Protocol Activation |
8/31/2022 |
NRG-DT001 Cohort B Closure Notice |
8/29/2022 |
Weekly Broadcast: NRG-GY022, NRG-BR007, GOG-0210, NRG-GY006, NRG-GY018, NRG-GY020, NRG-HN006 |
8/22/2022 |
Weekly Broadcast: NRG-GU002, NRG-GY018, NRG-GY022, NRG-BR007, NRG-GI005, NRG-GU012, NRG-GY006, NRG-GY020, GOG-0210 |
8/15/2022 |
Weekly Broadcast |
8/11/2022 |
NRG-HN001: QOL Study: FACT-NP and EQ-5D for newly enrolled patients |
8/8/2022 |
Weekly Broadcast: NRG-GY022, NRG-GI008, NRG-GI005, NRG-GY018 |
8/1/2022 |
Weekly Broadcast: NRG-GY022, NRG-CC007CD, NRG-CC009, NRG-BN003, NRG-GI005, NRG-GU010, NRG-GU012, GOG-0210, NRG-GY019 |
7/25/2022 |
Weekly Broadcast: NRG-CC003, RTOG 1112, NRG-GU009, NRG-GU010, NRG-LU006 |
7/18/2022 |
Weekly Broadcast |
7/11/2022 |
Weekly Broadcast: NRG-CC005, NRG-GY027, NRG-LU006 |
7/11/2022 |
NRG-GU007: Temporary Closure |
7/5/2022 |
Weekly Broadcast: NRG-GU012, NRG-GY029, NRG-BN010, NRG-CC005, NRG-GI005, NRG-GU007, GOG-0210, GOG-0212, GOG-0259, GOG-0264, GOG-0267, GOG-0268, GOG-0279, GOG-0283, NRG-CC008, NRG-LU006 |
6/29/2022 |
NRG-BN010: Temporary Closure |
6/27/2022 |
Weekly Broadcast: NRG-GY027, NRG-LU005, NRG-BN003, NRG-CC005 |
6/21/2022 |
Weekly Broadcast: NRG-GI008, NRG-CC003, NRG-GY014, NRG-BR004, NRG-CC005, RTOG 1112, GOG-0210 |
6/17/2022 |
NRG-CC003: Closure |
6/16/2022 |
NRG-GI008 Reopened to Accrual |
6/15/2022 |
RTOG 1112 Call for submission of data |
6/13/2022 |
Weekly Broadcast: RTOG 1112, NRG-GY012, NRG-HN008, NRG-GU005, NRG-CC005, GOG-0210, NRG-GY014 |
6/6/2022 |
Weekly Broadcast: NRG-CC005, NRG-CC009, NRG-GY018, NRG-BR002, NRG-GI008, NRG-GU005, NRG-BR004, GOG-0210, NRG-GY014 |
6/6/2022 |
NRG-GU005: Closure Notice |
6/3/2022 |
NRG-GI008: Temporary Accrual Hold |
6/3/2022 |
FORTE Study: NRG-CC005 Amendment 4 Activation |
5/31/2022 |
Weekly Broadcast: NRG-GY022, NRG-CC005, NRG-GU007, GOG-0210, NRG-GY014 |
5/24/2022 |
NRG-GY022: Temporary Closure on June 1, 2022 |
5/23/2022 |
Weekly Broadcast: NRG-GY012, NRG-BR004, GOG-0261, NRG-GY014, NRG-GY024, NRG-LU006 |
5/20/2022 |
NRG-BR004 Study Closure |
5/20/2022 |
NRG Oncology Study Terminations |
5/16/2022 |
Weekly Broadcast: NRG-BN001, NRG-GY022, NRG-BR003, NRG-BR004, NRG-BR007, NRG-GI004, NRG-GI005, NRG-GI008, NRG-CC005, GOG-0210, NRG-GY014, RTOG 1216, NRG-LU006 |
5/2/2022 |
Weekly Broadcast: NRG-BN004, NRG-BR004, NRG-GY014, NRG-GU005 |
4/29/2022 |
NRG-BR004 Temporary Closure |
4/25/2022 |
NRG-BN007 Temporary Closure |
4/25/2022 |
Weekly Broadcast: NRG-GY022, NRG-BR007, NRG-GI008, GOG-0210, GOG-0225, GOG-0238, GOG-0263, GOG-0278, GOG-0286B, NRG-GU007, NRG-HN008 |
4/18/2022 |
Weekly Broadcast: NRG-BN007, NRG-BN011, NRG-BR003, NRG-CC005. NRG-GI008, NRG-GU011, GOG-0210, NRG-GY018 |
4/15/2022 |
NRG-GY018 Central Monitoring Update |
4/11/2022 |
Weekly Broadcast: NRG-BR003, GOG-0263, NRG-GY022, NRG-BN010, GOG-0210 |
4/4/2022 |
Weekly Broadcast: GOG-0263, NRG-GY018, NRG-HN004, NRG-GU005, NRG-GY022, NRG-BR003, NRG-BR004, GOG-0210 |
3/30/2022 |
NRG-BR003 Upcoming Closure to Accrual |
3/28/2022 |
Weekly Broadcast: NRG-GU011, NRG-LU005, NRG-GY022, NRG-GI008, NRG-GU010, NRG-GU011, GOG-0210 |
3/21/2022 |
Weekly Broadcast: NRG-BN003, NRG-GY022, NRG-BR004, NRG-BR007, NRG-CC005, NRG-GI008, NRG-GU010, NRG-GU011, GOG-0210, GOG-0238, GOG-0258, NRG-LU006 |
3/17/2022 |
GOG-0238 Interim Analysis Results |
3/16/2022 |
NSABP B-55 Press Release Olaparib results |
3/15/2022 |
NSABP B-55: FDA approval & ESMO Plenary |
3/14/2022 |
Weekly Broadcast: NRG-GI008, NRG-GU005, NRG-GI005, NRG-GI007, NRG-GU010, NRG-GU011, NRG-HN006, NRG-LU006 |
3/10/2022 |
NRG-GI008 Protocol Activation |
3/7/2022 |
Weekly Broadcast: RTOG 0724, NRG-BN007, NRG-GY022, NRG-CC009, NRG-BN009, NRG-GI004, GOG-0210 |
3/2/2022 |
General Information on Potential Drug-Interactions of Concomitant CTEP IND Agents and the SARS-CoV-2 Antiviral Drug PAXLOVID |
2/28/2022 |
Weekly Broadcast: NRG-GY014, NRG-GY025, NRG-GI007, RTOG 0724, NRG-GY012, NRG-DT001, NRG-GY022, NRG-BN010, NSABP/NCIC MA.32F, NRG-GI004, NRG-GU008, NRG-GU009, NRG-GU010, GOG 0210 |
2/22/2022 |
NRG-GY012: Temp Closure |
2/21/2022 |
Weekly Broadcast: NRG-GY014, NRG-BR004, NRG-BR007, NRG-GU008, NRG-GU009, GOG-0210, RTOG 1308 |
2/14/2022 |
Weekly Broadcast: NRG-GY014, NRG-GY024, NRG-GY025, NRG-GY005, NRG-HN006, RTOG 1216, NRG-GU007 |
2/9/2022 |
First Participant Enrolled on FORTE |
2/4/2022 |
NRG-BR004 Amendment 5 Activation |
1/31/2022 |
Weekly Broadcast |
1/24/2022 |
Weekly Broadcast: NRG-BR004, NRG-CC005 (FORTE) |
1/17/2022 |
Weekly Broadcast: RTOG 1005, NRG-CC005, NRG-GI004, NRG-GI005, NRG-GU011, NRG-LU005 |
1/10/2022 |
Weekly Broadcast: NRG-BR004, NRG-GI007, NRG-GU008, NRG-GU009, NRG-LU005 |
1/3/2022 |
Weekly Broadcast: NSABP B-55, NRG-CC005, GOG-0274, NRG-HN009 |